FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

		Table I - Nor	n-Derivative Securities Acquired, Disposed of, or Bene	eficially Owr	ned			
(City)	(State)	(Zip)						
(Street) STATEN ISLAND	NY	10305			Form filed by More tha	n One Reporting Person		
259 LIBERTY	PHARMACEUTI	UALS, INC.,	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi X	, , ,			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/06/2025		Officer (give title below)	Other (specify below)		
1. Name and Ado <u>Sailer Carl</u>	dress of Reporting Per	son*	2. Issuer Name and Ticker or Trading Symbol <u>Acurx Pharmaceuticals, Inc.</u> [ACXP]		ionship of Reporting Pers all applicable) Director	on(s) to Issuer 10% Owner		
issuer that is in affirmative def	ale of equity securities of ntended to satisfy the fense conditions of Rule e Instruction 10.	the						

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securities Ac Disposed Of (D			Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	01/06/2025	Р		24,631(1)	Α	\$1.015	137,183	D	
Common Stock							5,000	Ι	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execu urity (Instr. or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date, if any (Month/Day/Year)	xecution Date, Transactio				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Warrants for Common Stock	\$0.9	01/06/2025		Р		24,631 ⁽²⁾		01/07/2025	01/07/2030	Common Stock	24,631	\$ <mark>0</mark>	24,631	D	

Explanation of Responses:

1. Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.

2. Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.

/s/ Kostantinos Skordalos, Power 01/08/2025 of Attorney For: Carl V. Sailer ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.